Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on PAG. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN116751278B reveals a novel fragment condensation method for Glepaglutide, offering high purity and scalable production for pharmaceutical supply chains.
Patent CN117186035A details a high-yield synthesis for empagliflozin intermediates. Discover cost-effective manufacturing and reliable supply chain solutions for pharmaceutical production.
Patent CN114507186A reveals a safer Eltrombopag synthesis avoiding hydrogenation. Discover cost-effective, high-purity manufacturing solutions for supply chain optimization.
Discover a novel MnO2-catalyzed synthesis for Avatrombopag N-Oxide impurity. Enhanced yield and purity for reliable pharmaceutical intermediate supply chains.
Novel patent CN120518600A details high-yield Empagliflozin synthesis. Reduces steps and enhances supply chain reliability for pharmaceutical intermediates globally.
Patent CN101830796B details a hydrolysis method for 3-ethyoxyl-4-carboxylphenylacetic acid. This route offers stable yields and simplified supply chain logistics for pharmaceutical manufacturers.
Novel Grignard coupling route for Dapagliflozin intermediate offers high purity and yield, reducing costs for pharmaceutical manufacturing.
Efficient preparation of Eltrombopag intermediate via palladium-free cyclization reducing costs and environmental impact for API manufacturing.
Patent CN102702138B details a novel adsorption and alkali treatment method for Repaglinide, achieving >99.6% purity and offering significant cost reduction in API manufacturing.
Patent CN104961715A details a high-purity Dapagliflozin method. Achieve cost reduction in API manufacturing with scalable, safe chemical processes.
Novel patent CN105622382B offers high-yield synthesis for Dapagliflozin intermediates with reduced waste and cost efficiency for global supply chains.
Advanced synthesis method for dapagliflozin intermediates offering enhanced purity and streamlined processing for reliable pharmaceutical supply chains.
Patent CN114380774A details a novel low-temperature synthesis for Empagliflozin Impurity I, ensuring high-purity reference standards and robust supply chain reliability for SGLT2 inhibitor manufacturing.
Novel patent CN117756611A offers efficient synthesis of dapagliflozin intermediate. Enhances supply chain reliability and reduces manufacturing complexity for pharmaceutical partners.
Analyze patent CN114591227A for Evatanepag production. Discover cost-effective, scalable routes for high-purity pharmaceutical intermediates and supply chain optimization.
Patent CN114072386A details improved palladium coupling for Eltrombopag intermediates, offering high purity and scalable supply chain solutions for global pharmaceutical manufacturers.
Novel patent CN115322110A offers a greener, scalable route for Eltrombopag intermediates, reducing toxic reagent reliance and enhancing supply chain stability for pharmaceutical manufacturers.
Novel preparation method for SGLT-2 inhibitors via selective TMS deprotection. Reduces steps, eliminates column chromatography, ensures high purity for API manufacturing.
Patent CN114478454A reveals a convergent synthesis for SGLT2 inhibitors, offering significant cost reduction in API manufacturing and improved supply chain reliability.
Patent CN112852769A reveals a high-yield enzymatic route for (S)-1-(2-methoxy-3-bromophenyl) ethanol. Discover cost-effective, green manufacturing solutions for this critical API intermediate.